India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
The company operates in over eight cities and the start-up plans to expand its reach to over 100 non-metro cities in the next 18-24 months
A high-value proposition recyclable film packed with industry-leading barrier and metal bond performance, sustainability quotient and U.S. FDA compliant
The Mission will simplify hospital processes and will increase Ease of Living. Under this, every citizen will get a digital health ID and their health record will be digitally protected.
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
